Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals

JOURNAL OF CONTROLLED RELEASE

卷:235

Article

Sun, Bo¹  Taha, Maie S.^1,2  Ramsey, Benjamin³  Torregrosa-Allen, Sandra³  Elzey, Bennett D.^3,4  Yeo, Yoon^1,5 

[1] Purdue Univ, Dept Ind & Phys Pharm, 575 Stadium Mall Dr, W Lafayette, IN 47907 USA

[2] Cairo Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt

[3] Purdue Univ, Ctr Canc Res, Biol Evaluat Shared Resource, 201 S Univ St, W Lafayette, IN 47907 USA

[4] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA

[5] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA

关键词: Nanocrystals;    Intraperitoneal chemotherapy;    Hydrogel depot;    Drug delivery;    Ovarian cancer;   

DOI  :  10.1016/j.jconrel.2016.05.056

来源: Elsevier

【 摘 要 】

Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of ovarian cancer, but the full potential is yet to be realized. To facilitate IP chemotherapy of ovarian cancer, we developed an in-situ crosslinkable hydrogel depot containing paclitaxel (PTX) nanocrystals (PNC). PNC suppressed SKOV3 cell proliferation more efficiently than microparticulate PTX precipitates (PPT), and the gel containing PNC (PNC-gel) showed a lower maximum tolerated dose than PPT-containing gel (PPT-gel) in mice, indicating greater dissolution and cellular uptake of PNC than PPT. A single IP administration of PNC-gel extended the survival of tumor-bearing mice significantly better than Taxol, but PPT-gel did not. These results support the advantage of PNC over PPT and demonstrate the promise of a gel depot as an IP drug delivery system. (C) 2016 Elsevier B.V. All rights reserved.

【 授权许可】

Free